Incyte Corporation
1801 Augustine Cut-Off
Wilmington
Delaware
19803
United States
673 articles about Incyte Corporation
-
Incyte Names New Member to Its Board of Directors - October 04, 2022
10/4/2022
Incyte announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors.
-
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
10/3/2022
Incyte announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo.
-
Incyte Corporation will acquire privately-held Villaris and AmplifyBio will acquire PACT Pharma, while Estrella will gain a spot on the Nasdaq Exchange.
-
The FDA is keeping busy as summer winds down, with approvals, Orphan Drug Designations and other actions. Here’s what the agency has been up to this week.
-
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
8/26/2022
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre® (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.
-
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
8/24/2022
Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2022 European Academy of Dermatology and Venereology (EADV) Congress, held September 7-10, 2022, in Milan and virtually.
-
Incyte to Present at Upcoming Investor Conference - Aug 23, 2022
8/23/2022
Incyte announced that it will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 12:30 p.m. in New York.
-
This week holds moments of truth for Provention's type 1 diabetes drug and bluebird bio's gene therapy for beta-thalassemia. Amicus and Incyte are coming up at the end of the month.
-
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
8/2/2022
Incyte (Nasdaq:INCY) today reports 2022 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.
-
The FDA has approved Incyte's Opzelura as the first and only at-home therapy for repigmentation in nonsegmental vitiligo.
-
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
7/19/2022
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
-
Mid-July is a relatively quiet time for the FDA in terms of drug approvals, but Incyte and Arcutis will have all eyes on the regulator as they await decisions in vitiligo and psoriasis.
-
Incyte to Report Second Quarter 2022 Financial Results
7/12/2022
Incyte announced that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 2, 2022.
-
MorphoSys is having a busy week after entering into an equity participation agreement with HIBio and a supply agreement and clinical collaboration with Pfizer and Incyte.
-
MorphoSys U.S. Inc., Pfizer and Incyte are teaming up to test Pfizer’s TTI-622 in conjunction with Monjuvi plus lenalidomide in patients with lymphoma.
-
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
6/14/2022
Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration has approved OLUMIANT®, a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata, available as 4-mg, 2-mg and 1-mg tablets.1 The recommended dose is OLUMIANT 2-mg/day, with an increase to 4-mg/day if treatment response is inadequate.
-
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
6/13/2022
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi ® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47.
-
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
5/26/2022
Incyte announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 Congress.
-
Incyte to Present at Upcoming Investor Conference in June 2022
5/24/2022
Incyte announced that it will present at the 43rd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 14, 2022 at 8:00 a.m. /11 a.m. in Rancho Palos Verdes.
-
CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
5/20/2022
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT® (baricitinib) for the treatment of adults with severe alopecia areata (AA).